Objective:To investigate the incidence trends and clinicopathologic characteristics of papillary thyroid cancer (PTC). Methods:A retrospective analysis was conducting using the following data:3,766 cases with thyroid disease in the People's Hospital of Wuhan University between January 2001 and July 2013;and 977 cases with thyroid cancer in the Hubei Cancer Hospital between Janu-ary 2006 and July 2013. Results:The incidence of thyroid cancer increased significantly since 2008, ranging from 14.94%to 18.10%(P<0.05). In particular, the PTC cases ranged from 85.33%to 90.89%(P<0.05). A total of 1,416 cases were diagnosed as PTC with a male to female ratio of 1:3.75. The positive rate of neck lymph node metastasis (NLNM) was significantly different in terms of gender and age (P<0.05). Significant differences were also found between the unifocal group and the multifocal group;the positive rate of NL-NM was 77.94%in the latter group. The rate of NLNM in PTC was 72.29%, which had higher significance compared with Hashimoto's thyroiditis or with nodular goiter. Conclusion: The incidence of thyroid cancer is increasing. Cases involving males aged below 45 years old and with>1 cm tumor diameter and multifocal PTC are more likely to be complicated with NLNM.

OBJECTIVETo investigate the efficacy of 153Sm-EDTMP in the treatment of bone metastasis of prostate cancer (PCa) by comparison with zoledronic acid.

METHODSWe assigned 55 PCa patients with bone metastasis to receive 153Sm-EDTMP (n = 31) and zoledronic acid (n = 24), the former injected intravenously at the dose of 37.0 MBq/kg body weight, and the latter administered by slow intravenous drip at 4 mg in 100 ml of 0.9% sodium chloride. We performed 99mTc-MDP bone scan before and 1 -2 months after the treatment.

RESULTSThe rate of pain relief was 83.9% in the 153Sm-EDTMP group and 58.3% in the zoledronic acid group (P = 0.035), and that of bone metabolism change was 64.5% in the former and 33.3% in the latter (P = 0.022).

CONCLUSION153Sm-EDTMP is an ideal agent for the treatment of prostate cancer with bone metastasis.

Aged ; Aged, 80 and over ; Bone Neoplasms ; drug therapy ; secondary ; Diphosphonates ; therapeutic use ; Humans ; Imidazoles ; therapeutic use ; Male ; Middle Aged ; Neoplasm Metastasis ; drug therapy ; Organometallic Compounds ; therapeutic use ; Organophosphorus Compounds ; therapeutic use ; Prostatic Neoplasms ; drug therapy ; pathology

This study was aimed to develop a sandwich ELISA kit for the diagnosis of bovine tuberculosis.And it was applied and evaluated in the quarantine of bovine tuberculosis.We established a bovine IFN-γ release method in vitro and developing three batches of kits.The sensitivity,repeatability and retention period of the kit were all evaluated.Totally 961 serum samples were tested using the developed sandwich ELISA kit tuberculin skin test and a commercial ELISA kit.Our results showed that the detection limit of this ELISA was 8.21 mg/mL.The repeatability tests showed good reproducibility in the intraassay and inter-assay.At the same time,the retention period of the kit was more than 12 months.Compared with the tuberculin skin test,the positive coincidence rate was 70.59％ and the negative coincidence rate was 99.20％,while the total coincidence rate was 98.44％.And compared with the BOVIGAMTM kit,the positive coincidence rate was 91.30％ and the negative coincidence rate was 99.78％,while the total coincidence rate reached 99.58％.At the same time,the sensitivity and specificity of the sandwich kit were 85.00％ and 100％,respectively.We established a bovine IFN-γ release method in vitro and developing corresponding kits successfully have a good application prospect.

Objective To explore the typing and surgical methods on intrahepatic stone complicated with atrophy-hypertrophy complex.Methods The clinical data of 32 cases of intrahepatic stone complicated with atrophy-hypertrophy complex from January 2014 to December 2015 in Hunan Province Peopole's Hospital were retrospectively analysed.Results These 32 cases of atrophy-hypertrophy complex accounted for 1.9％ of admitted hepatolith patients.We divided the intrahepatic stone complicated with atrophy-hypertrophy syndrome into 5 types,and type-Ⅱ the most common.We performed operation combined with fiber choledochoscope to examine,smash and remove the stone.This methods could reduce the rate of residual stone to 6％.The liver will be partly atrophy with stones inside it,and the residual liver will become hypertrophy.Stones of intrahepatic bile duct lead to the change of the position of porta hepatis and straitness of primary bile duct,and the bile cannot smooth out.there will be lithogenesis and relapsing cholangitis.Patients were treated by intrahepatic biliary double-opening drainage,and followed-up for 12-36 months.There were no death cases,and the total effective rate was 94％.Conclusions Intrahepatic stones complicated with atrophy-hypertrophy complex could be diagnosed by CT scan.Selecting proper operation method to treat atrophy-hypertrophy complex may decrease residual stones and improve the quality of life.

Objective To explore the role of Rho kinase in vascular smooth muscle cell ( VSMC) proliferation induced by aldosterone ( ALD) and the effect of mineralcocorticoid receptor (MR).Methods The ex-pressions of Rho -kinase protein were detected by Western blot .VSMC proliferation was measured by [ 3 H] Thymidine incorporation.Results ALD could up-regulate the expressions of Rho -kinase protein in dose-and time-dependent manner , peak at 20 min and 100 nmol · L-1 . Eplerenone , mineralcocorticoid receptor antagonist , could significantly reverse these effects , indicating the activation of Rho -kinase pathway induced by ALD in VSMC was mediated by MR .ALD could significantly induce VSMC proliferation , which could be inhibited by eplerenone and Y-276329 ( Rho-kinase inhibitor ) , indicating the VSMC proliferation induced by ALD was mediated by MR and the activation of Rho -kinase pathway.Conclusion Rho-kinase pathway and MR play an important role in VSMC proliferation induced by ALD .

To explore the effect of tanshinone IIA (TanIIA) on the occurrence and development of breast cancer, we employed the mouse mammary tumor virus-polyomavirus middle T antigen (MMTV-PyMT) transgenic mice as a spontaneous breast cancer mouse model. Animal welfare and experimental procedures were in accordance with the regulations of the Animal Ethics Committee of Nanjing University of Chinese Medicine. The animals were divided into control group, low-dose TanIIA treatment group (30 mg·kg^-1·day^-1), and high-dose TanIIA treatment group (60 mg·kg^-1·day^-1). The treatment was administered orally and daily for 5 weeks. The mice were sacrificed after final treatment. Mammary gland and lung were collected for histopathology studies. We evaluated the chemoprophylaxis effect of TanIIA on breast cancer in mice according to the pathological characteristics of breast cancer at different stages of development. Immunofluorescence staining were employed for blood vessel analysis. The expression levels of E-cadherin, proliferating nuclear antigen (PCNA), and oncogene c-Myc were detected by immunohistochemistry. Flow cytometry was used to analyze cell cycle and Cytoscape was used to construct drug-disease protein-protein interaction (PPI) network. Our results showed that TanIIA inhibits breast tumor progression by delaying malignancy from adenoma to early carcinoma, and inhibits blood vessel formation during tumor development. TanIIA (60 mg·kg^-1·day^-1) inhibits the expression levels of PCNA and c-Myc, upregulates the expression of E-cadherin. In addition, cell cycle experiments showed that the cell cycle of PyMT primary mammary cells in the high-dose TanIIA group was arrested in the G0/G1 phase. Our study demonstrated that TanIIA can significantly inhibit breast tumor progression in MMTV-PyMT mouse model, which may be related to the inhibition of angiogenic switch and cell cycle arrest.